​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 49 Wall Street analysts, predicts a 12-month average price target of $856.80, with a high of $1,030.00 and a low of $750.00. This represents a 6.43% increase from the last price of $805.02.

$600 $690 $780 $870 $960 $1 High: $1030 Avg: $856.8 Low: $750 Last Closed Price: $805.02

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 49 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 35 Buy (71.43%), 14 Hold (28.57%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 49 0 14 35 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals6.43%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts91873
Avg Price Target$869.22$841.89$824.49
Last Closing Price$805.02$805.02$805.02
Upside/Downside7.97%4.58%2.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 264149-128
Sep, 264149-128
Aug, 264149--27
Jul, 265168--29
Jun, 265168--29
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 19, 2026Piper Sandler$865.00$790.749.39%7.45%
Oct 14, 2026UBS$978.00$778.3625.65%21.49%
Oct 08, 2026Brian AbrahamsRBC Capital$810.00$730.0810.95%0.62%
Oct 08, 2026Chris RaymondRaymond James$911.00$742.1222.76%13.16%
Oct 07, 2026Truist Financial$780.00$747.514.35%-3.11%
Oct 07, 2026Morgan Stanley$779.00$743.604.76%-3.23%
Oct 01, 2026Jefferies$930.00$741.1625.48%15.53%
Oct 01, 2026Evan David SeigermanBMO Capital$920.00$741.4124.09%14.28%
Oct 01, 2026Argus Research$850.00$758.2712.10%5.59%
Sep 10, 2026Rajesh KumarHSBC$920.00$807.6513.91%14.28%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 19, 2026Piper SandlerOverweightOverweighthold
Oct 14, 2026UBSBuyBuyupgrade
Oct 08, 2026Raymond JamesOutperformOutperformhold
Oct 01, 2026JefferiesBuyBuyhold
Oct 01, 2026Cowen & Co.BuyBuyhold
Oct 01, 2026BMO CapitalOutperformOutperformhold
Sep 29, 2026RBC CapitalSector PerformSector Performhold
Sep 28, 2026CitigroupNeutralNeutralhold
Sep 10, 2026HSBCBuyBuyhold
Sep 01, 2026RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

$30 $40 $50 $60 $70 $80 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.40$40.51$37.05$40.90$43.07---
Avg Forecast$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %6.82%-4.91%-13.07%-9.15%-3.24%---

Revenue Forecast

$11B $13B $15B $16B $18B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.07B$12.17B$13.12B$14.20B$14.34B---
Avg Forecast$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %2.39%2.62%1.37%0.15%-1.95%---

Net Income Forecast

$3B $4B $5B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.08B$4.34B$3.95B$4.41B$4.50B---
Avg Forecast$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %10.75%-3.36%--14.28%3.36%---

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 49 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 35 Buy, 14 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 49 Wall Street analysts, averages $856.8 over the next 12 months. The price target range spans from $750 at the low end to $1.03K at the high end, suggesting a potential 6.43% change from the previous closing price of $805.02.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 6.43% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • October 2026: 14.29% Strong Buy, 50.00% Buy, 32.14% Hold, 0% Sell, 3.57% Strong Sell.
  • September 2026: 14.29% Strong Buy, 50.00% Buy, 32.14% Hold, 0% Sell, 3.57% Strong Sell.
  • August 2026: 14.81% Strong Buy, 51.85% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $48.41, marking a 12.40% increase from the reported $43.07 in 2025. Estimates for the following years are $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $15.52B, reflecting a 8.21% increase from the reported $14.34B in 2025. The forecast for 2027 is $17.22B, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.65B, representing an 3.12% increase from the reported $4.5B in 2025. Projections indicate $5.3B in 2027, and $6.95B in 2028.